In other recent news, CRISPR Therapeutics has filed a prospectus supplement with the U.S. Securities and Exchange Commission to offer and sell additional common shares worth up to $600 million. The ...
A new study published in Nucleic Acids Research unveils crucial advances in the engineering of CRISPR-associated transposons (CASTs)—a class of natural, RNA-guided DNA integration systems. According ...
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Crispr Therapeutics AG, with a price target of $80.00. The company’s shares opened today at $70.10. Take ...
Type V and VI CRISPR/Cas systems have emerged as promising cutting-edge diagnostic tools for nucleic acid detection. Nevertheless, the challenge of low target concentrations necessitates ...
Developing a gene therapy typically takes years, but when Baby KJ was diagnosed with a deadly genetic condition, scientists had only months. What followed was a successful collaboration among ...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day ...
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback